Welcome to our latest life science newsletter covering topical insurance and risk management issues in the industry.
In this issue, we look at orphan drugs and their inherent risks and challenges. We also have our usual features including a clinical trials update, mergers and acquisitions news from across the sector and a look at regulatory and legal developments.
This year we will be holding our ninth JLT Life Science Conference, The Science of Risk Management. 2015 was another challenging year for life science companies, merger and acquisition activity was unrelenting, although there was an unusually high number of products achieving regulatory approval to somewhat offset the well-publicised pipeline difficulties that many companies faced.
The JLT Life Science 2016 Conference is our ninth such event and topics to be discussed and debated this year include:
- Legal and regulatory changes that affect first and third party exposures, plus sessions on preparing and responding to some of these issues
- How data and analytics can be used to aid decision making. For more information and to register your interest in attending please click here.
Main feature in this issue:
The era of orphan drugs and their inherent risks and challenges
Orphan drugs are prescribed for rare diseases, largely affecting less than 200,000 patients in the US or less than five in 10,000 patients in the EU. The patient pool for orphan drugs is small, but their relatively low development cost, high price point and Food and Drug Administration (FDA) approvals have interested manufacturers.
Download Life Science newsletter
For further information, please contact Adrian Donald, Head of Life Science and Specialty Chemicals on +44 (0)20 7528 4193 or email email@example.com
Find out more about our Life Science capabilities.